Loading clinical trials...

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study

NCT01133080•Shalvata Mental Health Center

Summary

Double - Blind, Randomized, single centered study. The purpose of this study is to assess the feasibility of minocycline vs. placebo, added to atypical antipsychotic medications, for positive symptoms in adults suffering from schizophrenia.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and women 20-65 years of age.
•Primary DSM-IV diagnosis of Schizophrenia based on SCID for schizophrenia and confirmed by two senior psychiatrists.
•Patients who scored "moderate" (4) or higher on at least three of seven positive items in PANSS
•Initiated on treatment with atypical anti-psychotic medication.
•Capable and willing to provide informed consent
•Able to adhere to the treatment schedule
•Able to read, hear, write and speak the local language.
•Has signed a written informed consent to participate in the study

Exclusion Criteria

•Patients with acute, unstable, significant, or untreated medical illness besides schizophrenia including alcohol and drug dependence, or depression.
•Current suicidal ideation or history of a suicide attempt in the past 3 years
•Known or suspected pregnancy or women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse. or women who are breastfeeding
•Subjects who were taking a known contraindication to minocycline treatment.
•Subjects who had received treatment with minocycline or β-lactam antibiotics in the preceding half year before study entry.
•Subjects who were under compulsory hospitalization.

Locations (2)

Shalvata Mental Health Center

Hod HaSharon, Israel

shalvata MHC

Hod HaSharon, Israel

Key Dates

Start Date

June 1, 2010

Primary Completion Date

January 1, 2013

Completion Date

January 1, 2013

Last Updated

January 5, 2012

Enrollment

ESTIMATED participants

Conditions

Schizophrenia

Interventions

Minocycline

DRUG

placebo

DRUG

Contacts

yechiel levkovitz, MD, PhD

CONTACT

972-9-7478644 levkovit@netvision.net.il

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia